Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) just unveiled an announcement.
Jiangsu Recbio Technology Co., Ltd., a PRC-incorporated joint stock company listed in Hong Kong, has a diversified board that includes executive, non-executive and independent non-executive directors, chaired by non-executive director Xu Haoyu. This structure underscores its compliance with Hong Kong listing requirements and standard corporate governance practices.
The company has scheduled a board meeting for March 24, 2026 to review and approve its annual results for the year ended December 31, 2025 and to consider the publication of those results, as well as the potential payment of a final dividend. The announcement signals an upcoming disclosure of the company’s financial performance and possible shareholder returns, which will be closely watched by investors on the Hong Kong market.
The most recent analyst rating on (HK:2179) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 2179. The company is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a typical listed-company governance structure in the PRC market.
Average Trading Volume: 76,766
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.06B
For detailed information about 2179 stock, go to TipRanks’ Stock Analysis page.